The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.

And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.

The synthetic lethality specialist licenses in its second ADC in six months.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T. 

Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.